CytomX Therapeutics Inc logo

CTMX - CytomX Therapeutics Inc Share Price

$6.61 -0.1  -1.6%

Last Trade - 23/09/20

Sector
Healthcare
Size
Small Cap
Market Cap £240.0m
Enterprise Value £-32.3m
Revenue £67.0m
Position in Universe 3341st / 6393
Bullish
Bearish
Unlock CTMX Revenue
Momentum
Relative Strength (%)
1m +0.22%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -57.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
5.08 7.71 15.0 71.6 59.5 57.5 98.9 63.3 +62.5%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, CytomX Therapeutics Inc revenues increased 72% to $66.2M. Net loss decreased 92% to $3.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of 32% to $3.6M (expense), Stock-based Compensation in SGA decrease of 26% to $3.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CTMX Revenue Unlock CTMX Revenue

Net Income

CTMX Net Income Unlock CTMX Revenue

Normalised EPS

CTMX Normalised EPS Unlock CTMX Revenue

PE Ratio Range

CTMX PE Ratio Range Unlock CTMX Revenue

Dividend Yield Range

CTMX Dividend Yield Range Unlock CTMX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CTMX EPS Forecasts Unlock CTMX Revenue
Profile Summary

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated September 16, 2010
Public Since October 8, 2015
No. of Shareholders: 36
No. of Employees: 158
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 46,192,226
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CTMX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CTMX
Upcoming Events for CTMX
Frequently Asked Questions for CytomX Therapeutics Inc
What is the CytomX Therapeutics Inc share price?

As of 23/09/20, shares in CytomX Therapeutics Inc are trading at $6.61, giving the company a market capitalisation of £240.0m. This share price information is delayed by 15 minutes.

How has the CytomX Therapeutics Inc share price performed this year?

Shares in CytomX Therapeutics Inc are currently trading at $6.61 and the price has moved by -19.09% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CytomX Therapeutics Inc price has moved by -27.16% over the past year.

What are the analyst and broker recommendations for CytomX Therapeutics Inc?

Of the analysts with advisory recommendations for CytomX Therapeutics Inc, there are there are currently 1 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for CytomX Therapeutics Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will CytomX Therapeutics Inc next release its financial results?

CytomX Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the CytomX Therapeutics Inc dividend yield?

CytomX Therapeutics Inc does not currently pay a dividend.

Does CytomX Therapeutics Inc pay a dividend?

CytomX Therapeutics Inc does not currently pay a dividend.

When does CytomX Therapeutics Inc next pay dividends?

CytomX Therapeutics Inc does not currently pay a dividend.

How do I buy CytomX Therapeutics Inc shares?

To buy shares in CytomX Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CytomX Therapeutics Inc?

Shares in CytomX Therapeutics Inc are currently trading at $6.61, giving the company a market capitalisation of £240.0m.

Where are CytomX Therapeutics Inc shares listed? Where are CytomX Therapeutics Inc shares listed?

Here are the trading details for CytomX Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: CTMX
What kind of share is CytomX Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, CytomX Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CytomX Therapeutics Inc share price forecast 2020?

Shares in CytomX Therapeutics Inc are currently priced at $6.61. At that level they are trading at 99.24% discount to the analyst consensus target price of 0.00.

Analysts covering CytomX Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.05 for the next financial year.

How can I tell whether the CytomX Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CytomX Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -17.53%. At the current price of $6.61, shares in CytomX Therapeutics Inc are trading at -16.54% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CytomX Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for CytomX Therapeutics Inc.

Who are the key directors of CytomX Therapeutics Inc?

CytomX Therapeutics Inc's management team is headed by:

Sean McCarthy - CHM
W. Michael Kavanaugh - SVP
Frederick Gluck - IND
Elaine Jones - IND
Matthew Young - LED
Charles Fuchs - IND
Nick Galli - SVP
Lloyd Rowland - SVP
Amy Peterson - EVP
Carlos Campoy - CFO
Halley Gilbert - IND
Alison Hannah - SVP
Who are the major shareholders of CytomX Therapeutics Inc?

Here are the top five shareholders of CytomX Therapeutics Inc based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 7.78% (3.59m shares)
BVF Partners L.P. Hedge Fund
Percentage owned: 6.74% (3.12m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 5.74% (2.65m shares)
Perceptive Advisors LLC Private Equity
Percentage owned: 5.58% (2.58m shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 5.09% (2.35m shares)
Similar to CTMX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.